These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 34964276)

  • 1. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
    Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W; Liang J; Zhang D; Huang X; Lv Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
    Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
    Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
    Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
    Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
    Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D; Xu X; Wen J; Zhang C; Fan M
    Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung┬áCancer.
    Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
    J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
    Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
    Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L; Hou F; Liu Y; Li W; Zhang H
    J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
    Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
    Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
    Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
    Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
    Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
    Li C; Jia R; Liu H; Zhang B; Wang C
    Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.